The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | KEYNOTE-224: pembrolizumab monotherapy for previously untreated HCC
Jean-Luc Van Laethem, MD, PhD, Erasme Hospital University, Brussels, Belgium, discusses the results of the KEYNOTE-224 study (NCT02702414), a Phase II trial evaluating pembrolizumab monotherapy for previously untreated hepatocellular carcinoma (HCC). Checkpoint blockade in these patients demonstrated durable anti-tumor activity, promising overall survival, and no new associated safety signals. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
